These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18561577)

  • 1. Pharmacogenomics, ethics, and public policy.
    Peterson-Iyer K
    Kennedy Inst Ethics J; 2008 Mar; 18(1):35-56. PubMed ID: 18561577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ethics of pharmacogenomics.
    Neil D; Craigie J
    Monash Bioeth Rev; 2004 Apr; 23(2):9-20. PubMed ID: 15810202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical, social and legal implications of pharmacogenomics: a critical review.
    Moldrup C
    Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ethics, politics, and rights in pharmacogenomics].
    Bellver Capella V
    Rev Derecho Genoma Hum; 2002; (17):31-55. PubMed ID: 12703107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Property rights in genetic information.
    Spinello RA
    Ethics Inf Technol; 2004; 6(1):29-42. PubMed ID: 16969959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics: ethical issues and policy options.
    Buchanan A; Califano A; Kahn J; McPherson E; Robertson J; Brody B
    Kennedy Inst Ethics J; 2002 Mar; 12(1):1-15. PubMed ID: 12211263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patents and human genome research in developing countries: problems and proposals.
    Thambisetty S
    J World Intellect Prop; 2002 Sep; 5(5):685-723. PubMed ID: 15986548
    [No Abstract]   [Full Text] [Related]  

  • 8. The Human Genome Diversity Project: ethical problems and solutions.
    Resnik DB
    Politics Life Sci; 1999 Mar; 18(1):15-23. PubMed ID: 11660815
    [No Abstract]   [Full Text] [Related]  

  • 9. Privacy issues in second stage genomics.
    Robertson JA
    Jurimetrics; 1999; 40():59-76. PubMed ID: 14621715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethics and policy perspectives on personalized medicine in the post-genomic era.
    Landon MR
    J Biolaw Bus; 2005; 8(3):28-36. PubMed ID: 16459425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Harvard case of Xu Xiping: exploitation of the people, scientific advance, or genetic theft?
    Sleeboom M
    New Genet Soc; 2005 Apr; 24(1):57-78. PubMed ID: 16552917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.
    van Delden J; Bolt I; Kalis A; Derijks J; Leufkens H
    Bioethics; 2004 Aug; 18(4):303-21. PubMed ID: 15449404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Governing population genomics: law, bioethics, and biopolitics in three case studies.
    Winickoff DE
    Jurimetrics; 2003; 43(2):187-228. PubMed ID: 15156881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update to returning genetic research results to individuals: perspectives of the industry pharmacogenomics working group.
    Prucka SK; Arnold LJ; Brandt JE; Gilardi S; Harty LC; Hong F; Malia J; Pulford DJ
    Bioethics; 2015 Feb; 29(2):82-90. PubMed ID: 24471556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic databases and pharmacogenetics: introduction.
    Ashcroft RE; Hedgecoe AM
    Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):499-502. PubMed ID: 16980190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Returning genetic research results to individuals: points-to-consider.
    Renegar G; Webster CJ; Stuerzebecher S; Harty L; Ide SE; Balkite B; Rogalski-Salter TA; Cohen N; Spear BB; Barnes DM; Brazell C
    Bioethics; 2006 Feb; 20(1):24-36. PubMed ID: 16680905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and moral challenges of pharmacogenomics.
    Issa AM
    Natl Cathol Bioeth Q; 2001; 1(4):541-53. PubMed ID: 12854555
    [No Abstract]   [Full Text] [Related]  

  • 18. The 3-I framework: a framework for developing public policies regarding pharmacogenomics (PGx) testing in Canada.
    Bashir NS; Ungar WJ
    Genome; 2015 Dec; 58(12):527-40. PubMed ID: 26623513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications.
    Garrison LP; Carlson RJ; Carlson JJ; Kuszler PC; Meckley LM; Veenstra DL
    Drug Metab Rev; 2008; 40(2):377-401. PubMed ID: 18464050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical, social and legal issues in pharmacogenomics.
    Wertz DC
    Pharmacogenomics J; 2003; 3(4):194-6. PubMed ID: 12931132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.